A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: The international oncology study group CML1 study

Francis J. Giles, Jianqin Shan, Shanshan Chen, Suresh H. Advani, Iman Supandiman, Zeba Aziz, Alendry P. Caviles, Goh Yeow Tee, Martin R. Chasen, Zahira Fahed, Tsu Yi Chao, Ismet Aydogdu, Anne M. Lynott

研究成果: 雜誌貢獻文章同行評審

15 引文 斯高帕斯(Scopus)

摘要

A prospective randomized international study of 143 patients showed no apparent early survival advantage conferred by combining cytarabine, rather than hydroxyurea, with INF as first-line CML therapy. Combinations of alpha-interferon (INF) and chemotherapeutic agents are currently first-line therapy for the majority of patients with chronic myeloid leukemia (CML). The International Oncology Study Group conducted a prospective randomized study comparing INF combined with hydroxyurea or cytarabine. The primary study aim was to compare the survival durations in these patient cohorts. Patients with early chronic phase CML were randomized to receive INF 5 million units (Mu) given five times per week subcutaneously plus hydroxyurea or cytarabine as required to achieve a complete hematologic response and to maintain a WBC count between 2 x 109/L and 10 x 109/L and a platelet count between 75 x 109/L and 100 x 109/L. Therapy continued as tolerated unless progressive or blast phase disease occurred. At 36 months, the actuarial survival rate was equivalent in both groups: HI group (79 patients) survival was 85% (95% CI, 68-100%), as compared to 95% (95% CI, 79-100%) in the CI group (64 patients). In conclusion if seems that there is no apparent early survival advantage conferred by combining cytarabine, rather than hydroxyurea, with INF as first-line CML therapy.

原文英語
頁(從 - 到)367-377
頁數11
期刊Leukemia and Lymphoma
37
發行號3-4
DOIs
出版狀態已發佈 - 2000
對外發佈

ASJC Scopus subject areas

  • 血液學
  • 腫瘤科
  • 癌症研究

指紋

深入研究「A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: The international oncology study group CML1 study」主題。共同形成了獨特的指紋。

引用此